## Highlights of This Issue 1689

### REVIEW

1691

BH3 Mimetics: Status of the Field and New Developments  
Christian Billard

### SMALL MOLECULE THERAPEUTICS

1701

Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma  

1715

AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo  

### LARGE MOLECULE THERAPEUTICS

1774

Targeted Cytolysins Synergistically Potentiate Cytoplasmic Delivery of Gelonin Immunotoxin  
Christopher M. Pirie, Eline Van Valckenborgh, Hendrik De Raeve, Elke De Bryune, Song Xu, Ben Van Camp, Damian Handisides, Charles P. Hart, and Karin Vanderkerken

### CANCER THERAPEUTICS INSIGHTS

1783

Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells  

1796

Cyclin G1 Expands Liver Tumor-Initiating Cells by Sox2 Induction via Akt/mTOR Signaling  
Wen Wen, Tao Han, Cheng Chen, Lei Huang, Wen Sun, Xue Wang, Shu-Zhen Chen, Dai-Min Xiang, Liang Tang, Dan Cao, Gen-Sheng Feng, Meng-Chao Wu, Jin Ding, and Hong-Yang Wang
An Autocrine Loop between TGF-β1 and the Transcription Factor Brachyury Controls the Transition of Human Carcinoma Cells into a Mesenchymal Phenotype
Cecilia Larocca, Joseph R. Cohen, Romaine I. Fernando, Bruce Huang, Duane H. Hamilton, and Claudia Palena

Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect
Bart S. Hendriks, Stephan G. Klinz, Joseph G. Reynolds, Christopher W. Espelin, Daniel F. Gaddy, and Thomas J. Wickham

Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer
Yezi Zhu, Chengfei Liu, Nagalakshmi Nadiminty, Wei Lou, Ramakumar Tummala, Christopher P. Evans, and Allen C. Gao

Ethacrynic Acid Oxadiazole Analogs Induce Apoptosis in Malignant Hematologic Cells through Downregulation of Mcl-1 and c-FLIP, Which Was Attenuated by GSTP1-1
Guyue Liu, Rui Wang, Yuetong Wang, Pengzhan Li, Guisen Zhao, Linxiang Zhao, and Yongkui Jing

Sulindac Selectively Inhibits Colon Tumor Cell Growth by Activating the cGMP/PKG Pathway to Suppress Wnt/β-Catenin Signaling

Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional p53
Mayur A. Gadhikar, Maria Rita Sciuto, Marcus Vinicius Ortega Alves, Curtis R. Pickering, Abdullrah A. Osman, David M. Neskey, Mei Zhao, Alison L. Fitzgerald, Jeffrey N. Myers, and Mitchell J. Frederick

BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer

A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of Nitazoxanide
Hua Fan-Minogue, Sandhya Bodapati, David Solow-Cordero, Alice Fan, Ramasamy Paulmurugan, Tarik F. Massoud, Dean W. Felsher, and Sanjiv S. Gambhir

NF1 Deletion Generates Multiple Subtypes of Soft-Tissue Sarcoma That Respond to MEK Inhibition
Rebecca D. Dodd, Jeffrey K. Mito, William C. Eward, Rhea Chitalia, Mohit Sachdeva, Yan Ma, Jordi Barretina, Leslie Dodd, and David G. Kirsch

OBITUARY
O. Michael Colvin, MD: In Memoriam (1936–2013)

CORRECTIONS
Correction: MPT0B098, a Novel Microtubule Inhibitor That Destabilizes the Hypoxia-Inducible Factor-1α mRNA through Decreasing Nuclear–Cytoplasmic Translocation of RNA-Binding Protein HuR
ABOUT THE COVER

Continued androgen receptor (AR) expression and signaling is a key driver in castration-resistant prostate cancer (CRPC). AZD3514 is an orally bioavailable drug that inhibits androgen-dependent and -independent AR signalling \textit{in vitro} and \textit{in vivo}. Using immunohistochemistry, R3327H prostate tumors were scored for intensity of nuclear AR to assess the impact of AZD3514 on AR. For more details, see article by Lodick and colleagues on page 1715.